Wordt geladen...
Developmental Therapeutics in Myeloproliferative Neoplasms
The unprecedented success of the Janus kinase (JAK) 1/2 inhibitor ruxolitinib in myelofibrosis provided much-needed impetus for clinical drug development for the Philadelphia chromosome negative myeloproliferative neoplasms (MPN). The survival benefit conferred by this agent, along with its marked e...
Bewaard in:
| Gepubliceerd in: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Hoofdauteurs: | , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5540010/ https://ncbi.nlm.nih.gov/pubmed/28760302 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2017.02.014 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|